This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
| INTRODUCTION
Factor XII (FXII) is an 80-kDa glycoprotein with a plasma concentration of ~40 μg/mL (~500 nmol/L). 1, 2 Plasma FXII is mainly synthesized in the liver, but recently a leukocyte form of the protein has been recognized with unique functional activities. 3 FXII deficiency, called Hageman trait, was first recognized by Oscar Ratnoff as a defect that led to the prolongation of surface-activated blood coagulation tests, for example, partial thromboplastin time (PTT). 4 Ratnoff performed the PTT assay as part of his routine presurgical evaluation. The PTT was previously invented by Kenneth Brinkhous as an assay to recognize hemophilia, unlike the prothrombin time that was always normal with hemophilia plasma. 5, 6 Earl Davie was the first to purify Hageman factor and named it factor XII, according to the developing convention. 7 He and Ratnoff first showed that Hageman factor (FXII) activated plasma thromboplastin antecedent (factor XI [FXI) and later that FXIa activated factor IX (FIX). 8, 9 These observations were the basis for their formulation of the coagulation cascade hypothesis, simultaneously with R.G. MacFarland, and the contact activation hypothesis for the initiation of blood coagulation. 10, 11 The contact activation hypothesis for the initiation of blood coagulation fell from favor within a decade after its proposal for 2 reasons: (1) deficiencies of FXII, prekallikrein (PK), and high-molecular-weight kininogen (HK) (the latter 2 proteins were described in the next decade and are cofactors for FXII activation) are not associated with bleeding 2, 12, 13 ; and (2) no convincing physiologic surface was identified as a contact activator. Further, the appreciation of tissue factor and factor VII (FVII) as a physiologic activator of factor X (FX) provided a strong alternative hypothesis for initiation of blood coagulation activation. [14] [15] [16] Additionally, the recognition that FXI is activated by thrombin further provided an alternative pathway for FXIa formation, independent of FXII. 17, 18 However, FXII-initiated pathways have found new interest for several reasons. First, FXII, PK, and HK deficiencies in murine mod- . This review will not go into detail on this content area of FXII because contact activation of FXII has been covered in many reviews by us and others over the past 20 years. [29] [30] [31] [32] [33] FXII has the unique property to autoactivate from a zymogen into an Contact activation also is a major participant in gram-negative sepsis and sepsis from any cause. In Escherichia coli infections in baboons, FXII activation was associated with the hypotension seen in that disorder. 46 In this primate animal model, contact activation mainly provoked changes in vascular homeostasis due to bradykinin liberation and not blood coagulation activation through activation of FXI. In disorders such as prostate cancer and Alzheimer disease, there is evidence for a constitutively higher state of contact activation as a result of increased circulating cancer cell exosomes and denatured protein, respectively, in mouse models and human plasma samples. 27, 47 The largest single treatment-related contact activation is the exposure of patients to medical devices such as cardiopulmonary bypass, renal hemodialysis, extracorporeal membrane oxygenation (ECMO), left ventricular assist devices, and indwelling intravenous catheters. In the developed world, several million patients are exposed to these devices annually. Thrombosis in these devices is a major problem, and the present universal means to prevent device thrombosis is the use of unfractionated heparin from natural sources. In a series of investigations, the Colman and Edmund laboratories show that contact activation occurs in a simulated bypass model and that a variety of PKa inhibitors block it as well as platelet and neutrophil activation. [48] [49] [50] [51] A recent proof-of-concept study shows that a phage display Fab of an antibody to the catalytic region on FXIIa (3F7) reduced contact activation and fibrin deposition on infant membrane oxygenators used in simulated ECMO in rabbits. 52 These data suggest that inhibition of contact activation alone may be sufficient to block device surface-induced blood coagulation without increasing bleeding risk and exposing patients to the deleterious effects of heparin. To date, the only agent in clinical use that is effective to prevent device and catheter thrombosis is unfractionated heparin. 53 However, in experimental investigations, heparin along with several FXIIa inhibitors, corn trypsin inhibitor, and antisense oligonucleotides to FXIIa were effective at preventing catheter thrombosis. 53, 54 The approach to introduce FXIIa inhibitors as an alternative means to prevent complications of medical devices will be a slow, graduated process in the clinic, as no surgical team with long experience using heparin will immediately eliminate it for a newer agent whose mechanism(s) of action is not fully appreciated.
Investigations first will have to show that with contact activation inhibitors, lesser doses of heparin are sufficient to prevent device thrombosis.
| FXII ZYMOGEN -A PHYSIOLOGIC EFFECTOR OF CELL GROWTH, PROLIFERATION, AND ANGIOGENESIS
Although the enzymatic and coagulant activities of FXIIa have been known for a long time, the influence of zymogen FXII itself on (Figure 2 ).
The sum of these investigations shows that FXII has a sophisticated signaling system. FXII binding to uPAR signals through β1 integrins and the epidermal growth factor receptor (EGFR) to influence ERK1/2
and Akt phosphorylation. VEGFR2 further modifies this pathway but does not completely regulate FXII-induced signaling (Figure 2 ). Our studies also show that this pathway is mediated through β1 integrins, but other integrins may be operative as well.
F I G U R E 2 Factor XII signaling pathways leading to angiogenesis. Factor XII (FXII) binds to uPAR domain 2 (D2) to set up a signaling cascade resulting in endothelial cell growth, proliferation, and angiogenesis. High-molecular-weight kininogen blocks this pathway by blocking FXII binding to uPAR. uPAR interacts with β1 integrins and this pathway is blocked by mab 6S6. Through mechanisms not completely known, the integrin interacts with endothelial cell growth factor receptor (EGFR Finally, f12 −/− mice have fewer skin vessels constitutively and after 9 days of repair following a skin punch biopsy injury. 65 These combined data indicate that FXII has a previously unappreciated role in vessel growth and repair angiogenesis mediated through uPAR or CD87.
| INFLUENCE OF FXII ON VASCULAR SMOOTH MUSCLE CELLS AND FIBROBLASTS
FXII also stimulates pERK1/2 in cultured vascular smooth muscle cells. 68 In human lung fibroblasts, TGF-β1 induces p-JNK and translocation of SMAD-3 to the nucleus to upregulate FXII expression.
69
FXII upregulation is associated with increased pERK1/2, pAkt, and p38 since a JNK inhibitor and JNK and SMAD-3 antisense oligonucleotides did not block them. 69 In adult respiratory distress syndrome (ARDS), FXII levels are increased and colocalize with lung fibroblasts. 69 In bronchoalveolar lavage fluid from ARDS patients and controls, FXII levels are elevated, and the higher levels correlate with survival outcomes. 70 High FXII levels are associated with higher interleukin (IL)-8, IL-1β, IL-6, leukemia inhibitory factor, CXCL5, and tumor necrosis factor-α levels in human precision cut lung slices (PCLSs). 70 FXII also stimulates pERK1/2 and pAkt in PCLSs. 70 
| INFLUENCE OF FXII ON NEUTROPHIL FUNCTION
John Rebuck recognized that in skin windows placed on an FXII-deficient patient, there was less neutrophil migration. 71 The Colman laboratory recognized that FXIIa, but not FXII, has the ability to aggregate washed human neutrophils and cause degranulation. 72 This function, however, requires an intact heavy chain of FXII because βFXIIa, that is, the form of FXIIa without its heavy chain, does not have the ability to activate neutrophils. 72 We examined sterile wound punch biopsy specimens and observed that on days 2 and 5, f12 −/− mice have less neutrophil migration into the healing wounds. Akt2: α M β 2 expression, calcium mobilization, and histone H3 citrullination, NET formation over time 3 (Figure 3 ). 
| SUMMARY
Factor XII autoactivates into a pathophysiologic response agent, FXIIa, when it interacts with nonhuman (infectious agents) or human tissue (vessel wall collagen, DNA, RNA, polyphosphate, exosomes).
Also, FXIIa is formed when human plasma courses over artificial medical devices. Inhibitors to FXIIa should be useful to ameliorate the effects of these pathophysiologic interactions. Alternatively, zymogen FXII has biologic activity related to cell protection and repair.
In endothelium, FXII promotes neoangiogenesis and wound repair via uPAR and β1 integrins. In neutrophils, FXII promotes adhesion, migration, chemotaxis, and NETosis via uPAR and β2 integrins. Considering that FXII has more receptors than uPAR and uPAR interacts with more integrins than β1, additional interactions should be discovered.
| FUTURE PERSPECTIVES
These data suggest an exciting future for FXII and its related proteins. 
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